Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT

Molecular Imaging and Biology

Volumn 13, Issue 6, 2011, Pages 1234-1240

  Revheim, Mona Elisabeth ^a,b   Røe, Kathrine ^a,b   Bruland, Øyvind Sverre ^a,b   Bach Gansmo, Tore ^a   Skretting, Arne ^c   Seierstad, Therese ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

Author keywords

AHAX; Clinical PET CT scanner; GIST xenograft; Imatinib; Sunitinib

Indexed keywords

IMATINIB; PLACEBO; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG MONITORING; DRUG RESPONSE; DRUG UPTAKE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; IMAGE ANALYSIS; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL PROLIFERATION; DRUG MONITORING; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PYRROLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84855678563     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0464-0     Document Type: Article

References (41)

1. Miettinen M, Lasota J (2003) Gastrointestinal stromal tumors (GISTs): Definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54(1):3-24 (Pubitemid 36604461)
2. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152(5):1259-1269 (Pubitemid 28221878)
3. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22(18):3813-3825 (Pubitemid 41095223)
4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577-580 (Pubitemid 28067289)
5. Cassier PA, Blay JY (2010) Imatinib mesylate for the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther 10(5):623-634
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052-1056 (Pubitemid 32267975)
7. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626-632 (Pubitemid 351264358)
8. Shinomura Y, Kinoshita K, Tsutsui S, Hirota S (2005) Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol 40(8):775-780 (Pubitemid 41349232)
9. Novak C, Trevino JG (2010) Gastrointestinal stromal tumors: A paradigm for therapeutic options in solid organ tumors. Mini Rev Med Chem 10(7):624-634
10. Reichardt P (2010) Optimal use of targeted agents for advanced gastrointestinal stromal tumours. Oncology 78(2):130-140
11. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: Determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9(1):327-337 (Pubitemid 36109749)
12. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101(9):3597-3605 (Pubitemid 36857948)
13. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL et al (2009) Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 15(18):5902-5909
14. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760-1764 (Pubitemid 46797958)
15. Choi H (2008) Response evaluation of gastrointestinal stromal tumors. Oncologist 13(Suppl 2):4-7
16. Choi H, Charnsangavej C, de Castro FS, Tamm EP, Benjamin RS, Johnson MM et al (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183(6):1619-1628 (Pubitemid 44210530)
17. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25 (13):1753-1759 (Pubitemid 46797957)
18. Shinto A, Nair N, Dutt A, Baghel NS (2008) Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Clin Nucl Med 33(7):486-487
19. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E et al (2005) The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: Long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32(2):153-162 (Pubitemid 40248485)
20. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368(9544):1329-1338 (Pubitemid 44528723)
21. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764-4774 (Pubitemid 46630941)
22. Wolf G, Abolmaali N (2009) Imaging tumour-bearing animals using clinical scanners. Int J Radiat Biol 85(9):752-762
23. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP et al (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti- HER2 diabody. Cancer Res 65(4):1471-1478 (Pubitemid 40270176)
24. Seemann MD (2004) Human PET/CT scanners: Feasibility for oncological in vivo imaging in mice. Eur J Med Res 9(10):468-472
25. Aide N, Desmonts C, Briand M, Meryet-Figuiere M, Poulain L (2010) High-throughput small animal PET imaging in cancer research: Evaluation of the capability of the Inveon scanner to image four mice simultaneously. Nucl Med Commun 31(10):851-858
26. Revheim ME, Seierstad T, Berner JM, Bruland OS, Roe K, Ohnstad HO et al (2009) Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. Anticancer Res 29(11):4331-4336
27. Euhus DM, Hudd C, LaRegina MC, Johnson FE (1986) Tumor measurement in the nude mouse. J Surg Oncol 31(4):229-234 (Pubitemid 16104025)
28. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24 (3):148-154 (Pubitemid 19163397)
29. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D et al (2006) Impact of animal handling on the results of 18 F-FDG PET studies in mice. J Nucl Med 47(6):999-1006 (Pubitemid 46939953)
30. Leahy R, Byrne C (2000) Recent developments in iterative image reconstruction for PET and SPECT. IEEE Trans Med Imaging 19 (4):257-260
31. Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH (1998) High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. Phys Med Biol 43(4):1001-1013 (Pubitemid 28168428)
32. Qi J, Leahy RM (2000) Resolution and noise properties of MAP reconstruction for fully 3-D PET. IEEE Trans Med Imaging 19(5):493-506
33. Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin AK (2006) Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 66(10):5477-5486 (Pubitemid 43844976)
34. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD (2007) CT and PET: Early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 189(6):W324-W330
35. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA et al (2006) Consensus recommendations for the use of 18 F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47(6):1059-1066 (Pubitemid 46939960)
36. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26(33):5352-5359
37. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC et al (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216(1):64-74
38. Mena AC, Pulido EG, Guillen-Ponce C (2010) Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: Sunitinib. Anticancer Drugs 21(Suppl 1):S3-S11
39. Prenen H, Deroose C, Vermaelen P, Sciot R, biec-Rychter M, Stroobants S et al (2006) Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res 26(2A):1247-1252
40. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6 (4):249-251 (Pubitemid 40450717)
41. Skretting A (2009) Intensity diffusion 'is a better description than' partial volume effect. Eur J Nucl Med Mol Imaging 36(3):536-537